|Year to Date: $515.37M|
Seikagaku Corp. (Japan)
Triggered by enrollment of more than half the patients in a Phase IIb trial of CF101 in rheumatoid arthritis (10/23)
Genentech Inc. (NYSE:DNA)
Triggered by Genentech's filing of an IND to initiate Phase I trials of a small- molecule Hedgehog antagonist for treating cancer (10/5)
Sanofi-Aventis SA (France)
Triggered by Sanofi's initiation of clinical testing of AVE1642, an antibody that binds to the insulin-like growth factor 1 receptor (10/4)
Esprit Pharma Inc.
Triggered by submission of a new drug appli- cation with the FDA seeking approval of Sanctura for treating overactive bladder (10/18)
F. Hoffmann- La Roche Ltd. (Switzerland)
Triggered by Roche's decision to maintain its option to license MEM 3454, the lead compound from their deal on nicotinic alpha-7 receptor agonists for treating neurological disorders (10/31)
Triggered by Progenics' start of a Phase III trial of intravenous methylnaltrexone for treating postoperative ileus (10/25)
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
TEL = Tel Aviv Stock Exchange.